Loading clinical trials...

Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age

Evolution of IGF-1 in Children Born Small for Gestational Age and With Growth Retardation, Treated by Genotonorm Especially Evolution After Dose Adaptation.

NCT00174252•Pfizer

View on ClinicalTrials.gov

Summary

To estimate the percentage of children with serum IGF-1 \> 2 standard deviation (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment.

Eligibility

Age

4 - 9 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Chronological age between 4 and 9 years for a boy and 4 and 7 years for a girl.
•Measured Height \< -2.5 Standard Deviation

Exclusion Criteria

•Pubertal signs ie: testis volume \> or = 4 ml in boys and breast stage \> or = B2 (Tanner)
•Serious chronic disease (diabetes, renal insufficiency, heart failure, hepatic insufficiency, neoplasia)

Locations (22)

Pfizer Investigational Site

Amiens, France

Pfizer Investigational Site

Angers, France

Pfizer Investigational Site

Besançon, France

Pfizer Investigational Site

Bordeaux, France

Pfizer Investigational Site

Bron, France

Pfizer Investigational Site

Caen, France

Pfizer Investigational Site

Dunkirk, France

Pfizer Investigational Site

Lille, France

Pfizer Investigational Site

Limoges, France

Pfizer Investigational Site

Lorient, France

Key Dates

Start Date

February 1, 2005

Primary Completion Date

April 1, 2009

Completion Date

April 1, 2009

Last Updated

June 15, 2010

Enrollment

ACTUAL participants

Conditions

Fetal Growth Retardation

Interventions

Genotonorm (Somatropin)

DRUG

Validation of Sensors for Long-term Non-Invasive Fetal Monitoring

NCT06952777

Fetal Distress With Antenatal ProblemFetal Growth Retardation

View study

RECRUITING

Bioimpedence and Arterial Function Monitoring at Birth and in Infants

NCT04720690

Arterial StiffnessFetal Growth Retardation+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 15, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age

Inclusion Criteria

Exclusion Criteria

Validation of Sensors for Long-term Non-Invasive Fetal Monitoring

Bioimpedence and Arterial Function Monitoring at Birth and in Infants

Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction

Cardiac Displacement From Third Trimester to Early Childhood

Fetal Cardiac Function

Optimization of Cervical Collections in Pregnancy